Compounded semaglutide has been one of the most widely discussed topics in telehealth medicine over the past two years, and the regulatory landscape shifted meaningfully in 2025 and into 2026. Patients considering compounded GLP-1 therapy need to understand where things stand now, what changed, and how to evaluate whether a compounding program meets current safety and quality standards.

The explosive demand for semaglutide following its approval for weight management created a supply shortage that persisted for years. When a drug is on the FDA shortage list, compounding pharmacies are legally permitted to prepare copies of that drug to help meet demand. This is the regulatory mechanism that enabled the widespread availability of compounded semaglutide starting in 2022 and 2023.

At the height of the shortage period, hundreds of telehealth platforms and compounding pharmacies entered the market. Quality varied dramatically. Some compounding partners adhered rigorously to sterile compounding standards and used verified raw materials. Others cut corners in ways that created real patient safety risks.

The FDA announced in early 2025 that semaglutide had been removed from the shortage list. This had significant regulatory implications for compounding. Under federal law, FDA-approved drugs that are no longer in shortage cannot be compounded by standard compounding pharmacies (503A pharmacies) or by 503B outsourcing facilities for the purpose of making copies of the approved drug without a patient-specific clinical need.

This change did not immediately eliminate all compounded semaglutide from the market, and enforcement actions have unfolded gradually. The practical impact for patients is that the number of compounding programs that can legally operate in this space has narrowed, and platforms that are still legally offering compounded semaglutide in 2026 are doing so under specific regulatory frameworks.

Several pathways for legitimate compounded GLP-1 access remain available. Compounding for patients with documented clinical needs that cannot be met by the commercially available products, such as specific dose requirements not achievable with standard injectable pens, remains permissible. Combination formulations adding additional compounds like L-carnitine or B12 to semaglutide may also have a distinct regulatory status from simple semaglutide copies, though this is an area of ongoing regulatory interpretation.

Platforms operating in this space in 2026 should be able to clearly explain how their compounding program complies with current FDA guidance. Vague answers or claims that FDA guidelines do not apply to their model are significant red flags.

Regardless of regulatory status, the quality markers of a safe compounding program remain consistent. The pharmacy should hold a 503A or 503B registration and should be willing to provide documentation upon request. All injectable formulations should be prepared in a USP 797-compliant sterile facility. Third-party testing for potency, sterility, and endotoxin levels should be standard practice.

The telehealth platform should be transparent about which pharmacy they work with and should be able to provide information about that pharmacy's quality standards. Platforms that refuse to disclose their compounding partner or that provide only vague assurances about quality are not meeting the transparency standards appropriate for medical treatment.

Before starting any compounded GLP-1 program in 2026, ask: What is your compounding pharmacy's name and license number? How does your program comply with current FDA guidance on compounded semaglutide? Is the formulation third-party tested for potency and sterility? What is your response plan if FDA guidance changes in ways that affect your program?

These questions are not adversarial. A well-run program will answer them without hesitation. Difficulty answering these basic questions is itself informative.

The compounding safety concerns that emerged during the early growth of the GLP-1 telehealth market were largely concentrated in programs that bypassed quality standards. Well-run programs using licensed 503B outsourcing facilities with rigorous quality controls have safety records consistent with what you would expect from any pharmaceutical-grade injectable medication.

Patient safety in compounded GLP-1 therapy is not a binary question of safe versus unsafe. It depends entirely on the quality of the specific compounding program, which is why the questions above matter.


Individual results may vary. All prescriptions require approval by a licensed medical provider. Compounded medications are not FDA-approved. EllieMD facilitates access to independent healthcare providers and pharmacies and does not provide medical care or dispense medications.